Brief: Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial
20/05/2025 13:10
May 20 (Reuters) - Tourmaline Bio Inc TRML.O: TOURMALINE BIO ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE ONGOING PHASE 2 TRANQUILITY TRIAL EVALUATING PACIBEKITUG IN PATIENTS WITH ELEVATED HIGH-SENSITIVITY C-REACTIVE PROTEIN AND CHRONIC KIDNEY DISEASE TOURMALINE BIO INC - PACIBEKITUG ACHIEVES SIGNIFICANT HS-CRP REDUCTIONS THROUGH DAY 90 Source text: ID:nGNXb8kycJ Further company coverage: TRML.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tourmaline Bio
See all newsBrief: Novartis Completes Acquisition Of Tourmaline Bio
Brief: Novartis Announces Expiration Of Tourmaline Bio Tender Offer
Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports (updated)
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Tourmaline Bio
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy